[Hemorrheological survey in a group with arteriosclerotic vascular disease treated with suloctidil].
In 17 patients affected by atherosclerotic vascular disease and showing in basal conditions a hyperviscosity state, we have monitored the main hemorheological determinants during treatment with Suloctidil. At the end of treatment carried out for 5 months the results showed that erythrocyte filterability was the only hemorheological determinant influenced. The possible causes of this action are therefore considered.
D000368:Aged; D001157:Arterial Occlusive Diseases / Q000097:blood / Q000188:drug therapy*; D001809:Blood Viscosity; D004912:Erythrocytes / Q000502:physiology; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006400:Hematocrit; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000097:blood / Q000188:drug therapy*; D007866:Leg / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*; D012212:Rheology; D013468:Suloctidil / Q000627:therapeutic use*
D011412:Propanolamines; D005340:Fibrinogen; D013468:Suloctidil
Rilievi emoreologici in un gruppo di vasculopatici aterosclerotici trattati con suloctidil.